Undervalued Potential in Difficult-to-Treat RA: Buy Rating on Immunovant Driven by IMVT-1402’s Differentiated Profile and Underappreciated Market Opportunity

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Immunovant today and set a price target of $35.00.

Douglas Tsao has given his Buy rating due to a combination of factors tied to IMVT-1402’s differentiated profile and market opportunity. He views difficult-to-treat rheumatoid arthritis as a substantial, underappreciated commercial prospect, noting that Immunovant’s Phase 2b trial design, overenrollment, and focus on a more refractory, ACPA‑positive population could translate into a higher probability of clinical success and a favorable risk‑reward skew for the stock.

Tsao also highlights that prior setbacks with a competitor’s FcRn inhibitor in this setting are more a function of trial strategy than of the drug class, which leaves significant white space for IMVT-1402 to establish itself as a first‑in‑class option. Beyond RA, he sees additional upside from Graves’ disease, where key opinion leaders are encouraged by batoclimab’s proof‑of‑concept remission data and long‑term disease‑modifying potential, while the market appears to assign limited value, thereby limiting downside and supporting a constructive Buy recommendation.

Tsao covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Pacira Pharmaceuticals, and Rezolute. According to TipRanks, Tsao has an average return of 20.6% and a 53.52% success rate on recommended stocks.

In another report released yesterday, Guggenheim also reiterated a Buy rating on the stock with a $44.00 price target.